Facet Biotech
22
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
27.3%
6 terminated/withdrawn out of 22 trials
70.0%
-16.5% vs industry average
9%
2 trials in Phase 3/4
0%
0 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS
Role: collaborator
Prevention of Diabetes Progression Trial (PDPT)
Role: collaborator
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
Role: lead
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Role: lead
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
Role: lead
Study of Daclizumab in Patients With Chronic, Persistent Asthma
Role: lead
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
Role: lead
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
Role: lead
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
Role: lead
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Role: lead
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
Role: lead
Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
Role: lead
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
Role: lead
Research Study in Patients With Severe Ulcerative Colitis
Role: lead
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
Role: lead
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
Role: lead
A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
Role: lead
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Role: lead
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Role: lead
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
Role: collaborator